Calmette-Guerin (BCG) is the most effective agent for non-muscleinvasive bladder cancers, approximately 30% of patients treated with intravesical BCG fail to respond to this agent. Previous studies from our lab showed the potential linkage of estrogen/estrogen receptor signaling with the efficacy of BCG, yet the detailed mechanisms remain unclear. Our new data showed the combination of BCG and the anti-estrogen ICI 182,780 (ICI) or tamoxifen could lead to a better suppression of bladder cancer (BCa) than BCG alone.
INTRODUCTION AND OBJECTIVES: Although Bacillus
Calmette-Guerin (BCG) is the most effective agent for non-muscleinvasive bladder cancers, approximately 30% of patients treated with intravesical BCG fail to respond to this agent. Previous studies from our lab showed the potential linkage of estrogen/estrogen receptor signaling with the efficacy of BCG, yet the detailed mechanisms remain unclear. Our new data showed the combination of BCG and the anti-estrogen ICI 182,780 (ICI) or tamoxifen could lead to a better suppression of bladder cancer (BCa) than BCG alone.
METHODS: We first applied PCR to detect BCG internalization in two ERa positive BCa cell lines to investigate the potential effect of anti-estrogen ICI. Then, we used Q-PCR and western blot and examined the E2/ER effects on the integrin-a5b1 expression and the BCG attachment/internalization to BCa cells. To examine whether ICI can help the recruitment of macrophages toward BCa cells, we applied the transwell migration assay and in vivo mouse BCG model. Q-PCR, Elisa assay and MTT assay were used to detect the cytokine profile changes and BCa cell viability. For our in vivo studies, we applied the BBN-induced mouse BCa model, HE staining, BrdU and F4/80 staining to show the changes of macrophage infiltration and to prove the better efficacy of combining BCG plus anti-estrogen.
RESULTS: We found treatment with either 1 mM ICI or tamoxifen significantly increased the BCG attachment/internalization, and the neutralization of integrin-a5b1 could reduce the ability of the ICI enhanced BCG attachment/internalization to BCa cells ( Figure 1 ). Mechanism dissection revealed ICI could promote BCG attachment/ internalization to the BCa cells through targeting ERa and increased the integrin-a5b1 expression and IL-6 secretion. The increased cytokine production may enhance BCG-mediated suppression of BCa cell growth and TNF-a production via recruiting more monocytes/macrophages to BCa cells (Figure 2 -3). Consistently, in vivo studies found ICI could potentiate the anti-BCa effects of BCG in the carcinogen-induced mouse BCa models ( Figure 4) . CONCLUSIONS: Taken together, these in vitro and in vivo results suggest that combining BCG with the anti-estrogen may become a new therapeutic approach with better efficacy to suppress BCa progression and recurrence.
Source of Funding: none

MP65-13 FLAVOPIRIDOL AS A NOVEL AGENT FOR BLADDER CANCER
Reema Railkar, Thomas Sanford*, Mohammed Siddiqui, Spencer Krane, Piyush Agarwal, Bethesda, MD INTRODUCTION AND OBJECTIVES: Bladder cancer (CaB) is the 4th most common cancer among men in the US. It is among the most expensive malignancies to treat from diagnosis to death. There is an urgent need for the development of new treatment therapies. We utilized a quantitative high throughput screening (qHTS) technique to identify new therapies in two primary bladder cancer cell lines (T24 and UMUC3) and their metastatic lines (T24T, SLT3 and FL3 of T24 and LUL-2 for UMUC3) and further characterized one novel inhibitor: flavopiridol.
METHODS: We screened 7 bladder cancer cell lines (including RT4, T24, and UMUC3) against 1,912 oncology drugs using a 48-hour cell proliferation assay with an ATP-based readout (CellTiterGlo) to determine activity and potency of compounds in a dose response manner. One of the candidate drugs inhibitory in all cell lines tested was flavopiridol, a pan-CDK inhibitor. We further characterized the mechanism of action and in vivo effects of flavopiridol using various cell based assays and mouse xenograft studies.
RESULTS: The initial screen identified 95 compounds active in 7 cell lines. The top 50 compounds were further analyzed for molecular size of >200 g/mol and TPSA<90. This identified mitomycin C and 8 novel compounds. One of these compounds was flavopiridol which had an IC50 of 100-300nM in additional cell lines. Flavopiridol induces G2/M arrest; however, very little apoptosis was seen suggesting cytostatic rather than cytotoxic mechanism of action. Flavopiridol demonstrated dose dependent inhibition of migration, invasion and colony formation in CaB cell lines tested. Xenograft studies in rapidly growing UMUC-3 cells showed slowing of tumor growth but not complete reduction indicating cytostatic mechanism of flavopiridol. However, in slow growing cells, 5637, 5/8 treated mice showed complete tumor reduction.
CONCLUSIONS: qHTS can identify novel compounds. Flavopiridol seems to be a very effective inhibitor both in vitro and in vivo. Physical properties of Flavopiridol are most suited for intravesical use which may lead to it being an effective inhibitor of CaB in the bladder at higher doses without any/few systemic toxicities. Studies are underway to elucidate the use of flavopiridol as a single intravesical agent. Finally, combination therapy with intravesical chemotherapeutics shown to be e858 Previously, we reported a clinically applicable prognostic gene classifier for primary non-muscleinvasive bladder cancer (NMIBC). In the present study, we sought to perform long-term validation of this classifier in the prediction of muscleinvasive disease.
METHODS: We used previously published gene expression profiles from 176 NMIBC patients with extended follow-up. Progression was defined as development of muscle invasion or metastasis, and the progression risk score was calculated using the previously developed eight-gene progression classifier.
RESULTS: During median follow-up of 72.8 (interquartile range, 37.0-118.7) months, 26 (14.8%) patients progressed to muscle-invasive bladder cancer. The molecular progression risk score was significantly associated with clinicopathological variables, including tumor number, stage, grade, and multivariate risk assessment tools (P < 0.05 in each case). Multivariate Cox regression analysis revealed that molecular progression risk score was an independent predictor of development of invasive tumor, either as a continuous variable (hazard ratio, 1.489; 95% CI, 1.216-1.823; P < 0.001) or as a categorical variable (hazard ratio, 5.026; 95% CI, 1.619-15.608; P ¼ 0.005).
CONCLUSIONS: Our results confirm the clinical utility of the progression-related gene classifier for prediction of development of muscle invasion in NMIBC. The molecular progression risk score could aid in selecting patients who could benefit from more aggressive therapeutic intervention.
Source of Funding: none
MP65-15 COMPARISON OF GENOMIC ALTERATIONS IN BLADDER UROTHELIAL TUMORS WITH AND WITHOUT TELOMERASE REVERSE TRANSCRIPTASE PROMOTER MUTATION USING A NEXT-GENERATION SEQUENCING ASSAY
Sumit Isharwal*, François Audenet, Eugene Pietzak, Eugene Cha, Gopakumar Iyer, Ahmet Zehir, Barry Taylor, Michael Berger, Satish Tickoo, Victor Reuter, Jonathan Rosenberg, Dean Bajorin, Guido Dalbagni, Bernard Bochner, David Solit, Hikmat Al-Ahmadie, New York, NY INTRODUCTION AND OBJECTIVES: Telomerase reverse transcriptase (TERT) is the most frequently altered gene in urothelial cancer (UC), detected across all grades and stages of disease. We sought to characterize TERT alterations within a prospective cohort of UC treated at our institute and compare the frequency of genomic alterations in TERT promoter mutant vs wild-type UC specimens.
METHODS: Patients diagnosed with bladder urothelial tumors were enrolled onto an institutional review board approved prospective sequencing protocol. Tumor and matched germline DNA were analyzed for somatic point mutations, truncations, copy number alterations, and insertions/deletions using the MSK-IMPACT NGS assay that detects alterations in all exons and select introns of 410 oncogenes and tumor suppressor genes as well as the entire TERT promoter region.
RESULTS: 329 UC were sequenced of which 236 (71.7%) harbored TERT mutations, the majority being promoter region hotspots (chr5: 1295228 G>A [81%] and chr5:1295250 G>A [16%]). Patients with TERT promoter mutations were significantly older than those without (69.01 AE 10.70 years vs. 65.44 AE 11.78 years, p¼0.0317). UC with TERT promoter mutations had significantly higher mutation count [median 10 (range: 2-76) vs median 5 (range: 0-119)] as well as copy number alterations [median 0.11 (range: 0-0.68) vs median 0.047 (range: 0-0.65)]. In non-invasive UC, TERT promoter mutations were identified in 14 of 23 low grade (61%) and in 26 of 30 high grade (87%) tumors. Between UC with and without TERT promoter mutations, there was a very significant difference in mutation frequencies of ARID1A(34% vs 11%), PIK3CA(27% vs 13%), FGFR3(33% vs 16%), CREBBP(19% vs 4%), CDKN1A(17% vs 2%), ERBB2(26% vs 9%), ERCC2(15% vs 3%), TSC1(11% vs 0%), KMT2C(17% vs 9%) (all with p < 0.005).
CONCLUSIONS: TERT is the most frequently altered gene in bladder cancer with the majority of TERT alterations comprised of two hotspot mutations. UC with TERT promoter mutations tends to occur in older patients and is associated with overall higher mutation count and copy number alterations. A number of genes are differentially mutated in UC with and without TERT promoter mutations and may suggest a link between TERT promoter mutations and distinct mutations profiles in UC. (SqD) . Presence of SqD is associated with a basal molecular subtype and poor prognosis. Previous work identified decreased expression of the transcription factor Forkhead box A1 (FOXA1) in the urothelium as a marker of SqD, and that genetic ablation of Foxa1 in the bladders of mice results in SqD. However, it is
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